Happiest Minds Technologies Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/06z8kwtg1z39hcbjbjnylvfy.pdf

Key Takeaways


The AI First Pivot

Soota: "I want to assert that this development is an opportunity and not a threat for Happiest Minds, and we believe also for other IT services companies and in many ways, this reinforces the strategic choices we have been making."

Demand Environment & Pipeline


Segment & Vertical Performance

VerticalTrendCommentary
BFSI▲ Led growthExpecting Q4 uptick in Arttha license revenues and additional requirements from new-year planning.
Healthcare▲ StrongHealthy growth for three quarters across geos; a health-tech company moved from discovery to GenAI buildout; a large pharma customer that ramped down in Q2 ramped up again; a medical-supplies marketplace started new initiatives.
Industrial▲ Modest uptickShowed improvement during the quarter.
Edtech▼ DeclinedHeavy exposure to higher ed, especially US universities under severe pressure; now the third-largest vertical after being the largest. Risks have mostly played out; FY'27 should see stabilization and reversal via new institution-focused AI solutions.
Hi-tech▼ DeclinedA startup customer completed product development and ramped down; an Airport Authority of India support contract ended. Revenues expected to stabilize and grow in coming quarters; one large deal in advanced stage may contribute in Q4 or Q1.
Retail▼ DeclinedDrop of $500,000 QoQ driven by an extra billing cycle in Q2 normalizing, a small furlough, and a completed automation project at a beverage manufacturer. Follow-up work starts Q4; pipeline is encouraging.

Financials & Margins


People & Operations


Happiest Health & Stake-Sale Questions

Soota: "Now we have launched a major program which I am leading here along with Joseph and the whole team is here to work with this. That change in itself has 11 strategic programs. Make no mistake, I am here to completely see it through, and there is no change."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth10%-plus constant-currency growth reaffirmed4-year horizon
EBITDA marginMaintain 20-22% rangeCurrent financial year
AI/GenAI team sizeGrow to 1,000By end of FY'27
Guidance uplift"Significant increase" over the 10% growth commitment, with specific numbersAt Q4 results announcement
DSOBring back to 85 daysNo date; January showed stabilization
Edtech verticalStabilization and reversal of downward trendFY'27
Hi-tech verticalStabilization and growth; one large deal in advanced stage may contributeQ4 or Q1 FY'27
Retail verticalUptick in revenues as follow-up work beginsQ4
Investment returnsGenAI BU, NN sales and vertical capability investments to pay off and contribute to marginsFY'27
Happiest Health clinicsExpand from 6 to 26 clinicsWithin 12 months
Soota: "So do look out for our announcements at the end of Q4. And I think you will see a new trajectory from the company going ahead."

Key Metrics

MetricQ3 FY26
Revenue (USD)$65.7 million, +1.2% QoQ and +7.1% YoY in constant currency
Revenue (INR)₹588 crores, +2.4% QoQ and +10.7% YoY
Total income₹604 crores, +1.4% QoQ and +8.9% YoY
EBITDA₹123 crores, margin 20.4% vs 20.2% in Q2
Operating margin17.4%, up 40 bps sequentially from 17%
Profit before tax₹54.2 crores
Profit after tax₹40.3 crores
Adjusted PAT margin11.6%, up from 11% in Q2
One-time wage code charge₹22.3 crores, impacted PAT
Forex loss₹6.2 crores
9-month revenue (USD)$195.2 million, +10.2% YoY
9-month revenue (INR)₹1,711 crores, +12.8% YoY
9-month EBITDA margin20.6%
9-month adjusted PAT₹208 crores, vs ₹195 crores in prior year
GBS and AI services revenue growth~50% QoQ
IP-led sales10.4% of revenue
Utilization82%, highest in recent times, up from 80%
Attrition (trailing 12-month)17.4%, largely stable
Headcount6,548 employees
DSO92 days, up from 87 in Q2; target to bring back to 85 days
ROCE22%
ROE12%
Liquidity₹1,520 crores
GenAI and Agentic AI use cases32 moved from prototype, several scaling into production
New logos (H1 FY26)13, highest ever
AI/GenAI team target1,000 Happiest Minds by end of FY27
Full-year revenue growth guidance10% plus in constant currency
EBITDA margin guided range20% to 22%